Prokidney Financial Results
ProKidney Corp. reported third quarter 2026 financial results, ending the period with $141.9 million in cash and marketable securities to fund operations into mid-2027. The company remains on track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint topline results in Q2 2027. R&D expenses increased to $40.8 million, driven by clinical study and manufacturing costs for the ongoing rilparencel program.
- Term
- Q3 2026
“The third quarter marked continued progress for ProKidney, with PROACT 1 advancing toward full enrollment and our pivotal eGFR slope topline readout remaining on track for the second quarter of 2027. The data presented at Kidney Week further build the mechanistic and clinical evidence supporting rilparencel and provide a more cohesive picture of how it may stabilize kidney function. Together, these advances reinforce our confidence as we approach this important Phase 3 readout and continue our mission to transform the treatment of advanced CKD.”
Bruce Culleton, M.D., CEO of ProKidney